BRPI0817273A2 - Região constante de anticorpo modificada - Google Patents

Região constante de anticorpo modificada

Info

Publication number
BRPI0817273A2
BRPI0817273A2 BRPI0817273-0A BRPI0817273A BRPI0817273A2 BR PI0817273 A2 BRPI0817273 A2 BR PI0817273A2 BR PI0817273 A BRPI0817273 A BR PI0817273A BR PI0817273 A2 BRPI0817273 A2 BR PI0817273A2
Authority
BR
Brazil
Prior art keywords
constant region
modified antibody
antibody constant
modified
region
Prior art date
Application number
BRPI0817273-0A
Other languages
English (en)
Inventor
Tomoyuki Igawa
Hirotake Shiraiwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817273(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0817273A2 publication Critical patent/BRPI0817273A2/pt
Publication of BRPI0817273B1 publication Critical patent/BRPI0817273B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0817273-0A 2007-09-26 2008-09-26 Região constante de anticorpo humano com heterogeneidade cterminal reduzida e com amidação suprimida do aminoácido c-terminal, bem como anticorpos e composição farmacêutica BRPI0817273B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007250147 2007-09-26
JP2007-250147 2007-09-26
PCT/JP2008/067483 WO2009041613A1 (ja) 2007-09-26 2008-09-26 抗体定常領域改変体

Publications (2)

Publication Number Publication Date
BRPI0817273A2 true BRPI0817273A2 (pt) 2015-06-16
BRPI0817273B1 BRPI0817273B1 (pt) 2025-10-28

Family

ID=

Also Published As

Publication number Publication date
MY193526A (en) 2022-10-18
KR20160135850A (ko) 2016-11-28
CA2700394A1 (en) 2009-04-02
PH12018501459B1 (en) 2024-06-28
PE20090711A1 (es) 2009-07-15
CA2978687C (en) 2020-02-18
CL2008002886A1 (es) 2009-12-04
JPWO2009041613A1 (ja) 2011-01-27
AU2008304748A1 (en) 2009-04-02
KR20210024260A (ko) 2021-03-04
CA2700394C (en) 2017-10-24
KR102467302B1 (ko) 2022-11-14
SG193868A1 (en) 2013-10-30
JP5930503B2 (ja) 2016-06-08
EP3789400A1 (en) 2021-03-10
AR110887A2 (es) 2019-05-15
KR20180126633A (ko) 2018-11-27
HK1146728A1 (en) 2011-07-08
TW201429986A (zh) 2014-08-01
MX342551B (es) 2016-10-04
EP2194066B1 (en) 2016-03-09
KR102119108B1 (ko) 2020-06-04
CA3139492A1 (en) 2009-04-02
AR068563A1 (es) 2009-11-18
KR20100074221A (ko) 2010-07-01
JP2016026215A (ja) 2016-02-12
JP2019001794A (ja) 2019-01-10
ES2687808T3 (es) 2018-10-29
CA3066453C (en) 2022-01-11
IL204537A0 (en) 2010-11-30
RU2010116278A (ru) 2011-11-10
JP2022101707A (ja) 2022-07-06
DK2194066T3 (en) 2016-05-02
KR101922788B1 (ko) 2018-11-27
RU2014122609A (ru) 2015-12-10
PH12014502106B1 (en) 2015-12-07
EP2194066A1 (en) 2010-06-09
US9688762B2 (en) 2017-06-27
WO2009041613A1 (ja) 2009-04-02
KR102225009B1 (ko) 2021-03-08
JP2014144956A (ja) 2014-08-14
KR102339457B1 (ko) 2021-12-14
EP2194066A4 (en) 2010-12-15
PH12021552811A1 (en) 2022-11-21
PH12018501459A1 (en) 2019-11-11
CN101874041A (zh) 2010-10-27
CA3066453A1 (en) 2009-04-02
CA3139492C (en) 2024-04-30
EP3059246B1 (en) 2018-07-11
JP7072032B2 (ja) 2022-05-19
TWI464262B (zh) 2014-12-11
RU2526512C2 (ru) 2014-08-20
ZA201002422B (en) 2014-06-25
JP2021020949A (ja) 2021-02-18
MY180713A (en) 2020-12-07
JP6385386B2 (ja) 2018-09-05
MY163473A (en) 2017-09-15
US12600789B2 (en) 2026-04-14
SG10201605394SA (en) 2016-08-30
PL3059246T3 (pl) 2018-11-30
US20100298542A1 (en) 2010-11-25
JP5484060B2 (ja) 2014-05-07
EP3059246A1 (en) 2016-08-24
PH12014502106A1 (en) 2015-12-07
TW200925273A (en) 2009-06-16
JP2025128348A (ja) 2025-09-02
EP3415529A1 (en) 2018-12-19
JP2024012685A (ja) 2024-01-30
US11332533B2 (en) 2022-05-17
MX2010003450A (es) 2010-04-27
CA2978687A1 (en) 2009-04-02
KR101680906B1 (ko) 2016-11-30
AU2008304748C1 (en) 2014-06-12
TWI563002B (en) 2016-12-21
US20220251225A1 (en) 2022-08-11
KR20200062390A (ko) 2020-06-03
JP5868441B2 (ja) 2016-02-24
KR20210156290A (ko) 2021-12-24
DK3059246T3 (en) 2018-10-01
ES2566957T3 (es) 2016-04-18
EP3415529B1 (en) 2020-11-04
US20170342154A1 (en) 2017-11-30
AR110822A2 (es) 2019-05-08
AR117007A2 (es) 2021-07-07
AU2008304748B2 (en) 2014-01-16
CA3222170A1 (en) 2009-04-02
JP2016169220A (ja) 2016-09-23
CN101874041B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
CY2021027I2 (el) Σκευασματα αντισωματων anti-cd20
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0820819A2 (pt) Formulação de anticorpos
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
DK2131860T3 (da) Anti-sclerostin-antistoffer
PT2195026E (pt) Anticorpos anti-esclerostina
EP2150167A4 (en) SEMI-DISPOSABLE ENDOSCOPE
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0809677A2 (pt) Anticorpos anti-ige
PT3072906T (pt) Formulação de anticorpos
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
NO344963B1 (no) Humanisert antistoff
PT2376116E (pt) Anticorpos anti-igf
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2211903A4 (en) CLL-1 ANTIBODY
BRPI0810815A2 (pt) Dispositivo de fixação
EP2233838A4 (en) COOKER
BRPI0817427A2 (pt) Anticorpo anti-bst2
EP2207803A4 (en) Cd9-specific human antibodies
EP2300828A4 (en) SCREENING SYSTEM FOR ANTIGENS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.